Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04711837 |
Recruitment Status :
Completed
First Posted : January 15, 2021
Results First Posted : May 26, 2023
Last Update Posted : October 6, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Anesthesia | Drug: HSK3486 Drug: Propofol | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 255 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery. |
Actual Study Start Date : | February 11, 2021 |
Actual Primary Completion Date : | April 13, 2022 |
Actual Study Completion Date : | April 20, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: HSK3486
HSK3486 for induction of general anesthesia.
|
Drug: HSK3486
HSK3486 for induction of general anesthesia. |
Active Comparator: Propofol
Propofol for induction of general anesthesia.
|
Drug: Propofol
Propofol for induction of general anesthesia.
Other Name: Diprivan |
- Number of Participants With Successful Anesthesia Induction [ Time Frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes) ]The primary outcome of interest was the success rate of anesthesia induction, defined by the proportion of subjects with successful anesthesia. A subject was considered successful for anesthetic induction if the following conditions were met: induction success Modified Observer's Assessment of Awareness/Sedation Scale (MOAA/S ≤1) after administration of study drug and 1 or less top-up dose required without using any rescue drugs. Where Grade 0 is no response after trapezius squeeze, Grade 1 responds only after painful trapezius squeeze and Grade 5 is completely awake responds to name spoken in normal tone.
- Subjects' NRS Pain Score [ Time Frame: Up to 5 minutes ]Injection-site pain is evaluated verbally during study drug administration using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worse imaginable pain). Subjects' NRS pain score at the time of study drug administration (Day 1) and recall of pain score in PACU.
- Proportion of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression. [ Time Frame: 15 minutes from end of drug administration. ]The proportion of subjects with successful induction who maintain the desired depth of anesthesia for general elective surgery, AND without significant cardiac and respiratory depression between the time of successful induction and 15 minutes post initiation of study drug administration, or up to the beginning of second tracheal intubation attempt if it is a difficult condition and not beyond 15 minutes post initiation of study drug administration.
- Proportion of Subjects With Any Injection-site Pain on Numeric Rating Scale. [ Time Frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes) ]The proportion of subjects with any injection-site pain at time of drug administration on the Numeric Rating Scale (NRS ≥1).
- Time to Successful Induction of General Anesthesia. [ Time Frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes) ]Time from the end of the first administration of the study drug to MOAA/S ≤1.
- Time to the Disappearance of Eyelash Reflex [ Time Frame: From start of drug administration to disappearance of eyelash reflex (up to 5 minutes) ]Time from the end of the first administration of the study drug to the disappearance of eyelash reflex.
- Number of Participants That Failed to Meet Successful Induction of General Anesthesia [ Time Frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes) ]Failed to meet successful induction of general anesthesia defined by the use of the Top-up Study Drug and Rescue/Remediation Drugs
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Subjects undergoing elective surgery (nonemergency, noncardiothoracic, and nonintracranial surgery anticipated to last at least 1 hour ).
- Males or females, aged ≥18 years old, with American Society of Anesthesiologists Physical Status (ASA PS) I to IV.
- Body mass index (BMI) ≥18 kg/m2.
- For all females of childbearing potential, negative pregnancy test at screening and baseline. Additionally, females of childbearing potential must agree to use birth control (such as condom, intrauterine device [IUD], abstinence) from the time of consent until 30 days post study drug administration.
- Capable of understanding the procedures and methods of this study, willing to sign an Informed Consent Form, and to complete this study in strict compliance with the study protocol.
Exclusion Criteria:
- Contraindications to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
- Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subject having contraindications to propofol, opioids, and their antidotes.
- Medical condition or evidence of increased sedation/general anesthesia risk.
- Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study.
- Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics.
- Laboratory parameters significantly out of range at screening.
- Female subjects with a positive pregnancy test (serum or urine) at screening or baseline; lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
- Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04711837
United States, Arizona | |
Arizona Research Center | |
Phoenix, Arizona, United States, 85053 | |
United States, California | |
Lotus Clinical Research, LLC | |
Pasadena, California, United States, 91105 | |
United States, Florida | |
Phoenix Clinical Research, LLC | |
Tamarac, Florida, United States, 33321 | |
United States, Illinois | |
The University of Chicago Medicine | |
Chicago, Illinois, United States, 60637 | |
United States, New York | |
New York City Heath and Hospitals | |
New York, New York, United States, 10013 | |
Stony Brook University Hospital | |
Stony Brook, New York, United States, 11794 | |
United States, North Carolina | |
UNC Health Care System | |
Chapel Hill, North Carolina, United States, 27599 | |
Duke University | |
Durham, North Carolina, United States, 27705 | |
United States, Ohio | |
The Ohio State University Research Foundation | |
Columbus, Ohio, United States, 43210 | |
United States, Texas | |
HD Research | |
Bellaire, Texas, United States, 77401 | |
Plano Surgical Hospital | |
Plano, Texas, United States, 75093 | |
Endeavor Clinical Trials, LLC | |
San Antonio, Texas, United States, 78229 | |
United States, Utah | |
JBR Clinical Research | |
Salt Lake City, Utah, United States, 84107 |
Study Director: | William Daley, MD | Haisco-USA Pharmaceuticals, Inc. |
Documents provided by Haisco-USA Pharmaceuticals, Inc.:
Responsible Party: | Haisco-USA Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT04711837 |
Other Study ID Numbers: |
HSK3486-304 |
First Posted: | January 15, 2021 Key Record Dates |
Results First Posted: | May 26, 2023 |
Last Update Posted: | October 6, 2023 |
Last Verified: | October 2023 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Anesthesia Elective surgery Propofol |
Propofol Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs |
Anesthetics, Intravenous Anesthetics, General Anesthetics |